Die Forschung hat gezeigt, dass Cholesterin-Senker nicht nur das Risiko für Herz-Kreislauf-Erkrankungen reduzieren, sondern auch das Demenz-Risiko senken können.

AbstractWe report the genome-guided discovery, isolation, and characterization of floridanemastatin (1), a previously undescribed statine-containing polyketide−peptide from Floridanema evergladense BLCC-F167. Examination of the biosynthetic gene clusters in the F.evergladense genome revealed a hybrid PKS−NRPS biosynthetic gene cluster featuring an NRPS module followed by a PKS ketoextension and ketoreductase domain arrangement diagnostic of statine biosynthesis. Guided by this prediction, LC−MS-based analysis of cultured biomass led to the isolation of floridanemastatin. High-resolution mass spectrometry and comprehensive 1D and 2D NMR spectroscopy defined a polyketide−peptide scaffold incorporating serine, proline, a leucine-derived amino alcohol, and a statine-like residue identified as 4-amino-3-hydroxy-(4-hydroxyphenyl)pentanoic acid. Connectivity and residue assignments were consistent with the predicted biosynthetic logic of the gene cluster, including reductive chain termination to yield an alcohol. Although the statine pharmacophore and in silico target prediction suggested cathepsin D as a plausible target, enzymatic evaluation indicated that apparent inhibition was attributable to nonspecific aggregation under the assay conditions. These findings demonstrate the utility of biosynthetic gene cluster architecture for prospecting statine-containing cyanobacterial natural products and further highlights the genus Floridanema as a source of chemically distinctive specialized metabolites.

Se avete dedicato anche solo cinque minuti alla lettura di notizie mediche, avrete sicuramente visto titoli come: “Chi assume statine ha il 30% di attacchi di cuore in meno!” oppure &#8…

Prokuratūra dažnai nusipelno komplimentų dėl principingumo ir nepriklausomumo tiriant įvairias nusikalstamas veikas, kad ir vadinamųjų „čekistų“ bylas. Vis dėlto atsitinka taip, kad šaukštas deguto visą statinę medaus pagadina.

Millionen Menschen schlucken sie täglich gegen erhöhtes Cholesterin – nun deuten neue Befunde darauf hin, dass Statine weit mehr leisten als gedacht: Sie könnten das Demenzrisiko senken und Diabetikern einen zusätzlichen Nutzen bringen.

Das arznei-telegramm und die atd Arzneimitteldatenbank werden Ende 2026 eingestellt.

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS o "NewAmsterdam" o la "Società"), azienda biofarmaceutica che si occupa di sviluppo clinico in fase avanzata di farmaci orali, diversi dalle statine, per pazienti a rischio di malattie cardiovascolari ("CVD") con elevati livelli di colesterolo LDL, lipoproteine a bassa densità (“LDL-C”), per i quali le terapie esistenti non sono sufficientemente efficaci o ben tollerate, insieme al Gruppo Menarini (“ Menarini”), suo partner, ha annunciato che la Commissione Europea (CE) ha concesso l'autorizzazione all'immissione in commercio per Ubeslo® (obicetrapib 10 mg in monoterapia) ed Evlarco® (associazione a dose fissa di 10 mg di obicetrapib più 10 mg di ezetimibe) per il trattamento di pazienti con ipercolesterolemia primaria sia eterozigote familiare ("HeFH") che non familiare o dislipidemia mista, sancendo la prima approvazione regolatoria di obicetrapib al mondo.

Après 70 ans, une statine quotidienne évite des infarctus, sans prouver plus d’années de vie. Faut-il quand même la prendre pour protéger son cœur ?

Das arznei-telegramm und die atd Arzneimitteldatenbank werden Ende 2026 eingestellt.

ESC 2026 | STAREE: Nutzen-Risiko-Profil von Statinen bei gesunden älteren Menschen im Hinblick auf das krankheitsfreie Überleben. Von Prof. U. Laufs.